Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome
In recent years botulinum toxin type A has been introduced as a new symptomatic therapy for focal dystonias.' Generalised muscle weakness is reported after overdoses of botulinum toxin, but is a rare clinical phenomenon. However, botulinum toxin spreads to muscles distant from those injected, even in low doses, as shown by single fibre electromyography.2 There have been no reports of botulinum toxin in patients with a pre-existing alteration of neuromuscular transmission. In one of our patients suffering from blepharospasm local botulinum toxin injection uncovered a Lambert-Eaton myasthenic syndrome (LEMS).
A 63-year-old woman presented with a three year history of severe blepharospasm and mild oromandibular dystonia. A periorbital injection with a total dose of 12 nanograms of botulinum-toxin-A-complex (Porton Down, UK) had been performed in another hospital. After three days the blepharospasm had improved but a mild ptosis on the left eye, nausea, fatigue, and generalised muscle weakness had occurred, all of which resolved within eight weeks. Twelve weeks after the first injection, when we saw the patient for the first time, SFEMG of the right EDC-muscle showed no abnormality: fibre density 1-6, blockings 0%, MCD 22-2 ,us (upper limits of our laboratory: fibre density 1-9, mean MCD 38-0,us). The possible relation between the muscle weakness and the botulinum toxin injection remained unclear; the low dose would not be expected to cause generalised muscle weakness.
The blepharospasm recurred 20 weeks after the first treatment with botulinum toxin and the patient requested a further injection. We used a smaller total dose of 8 ng botulinum toxin. After four days the muscles of the pelvic and shoulder girdles became weak and fatigued. The patient had difficulties in rising from a chair and climbing stairs. We found normal motor conduction velocities in the peroneal and tibial nerves and normal sensory conduction velocity in the sural nerve. EMG of the right EDC muscle showed no abnormalities. Laboratory findings of blood and CSF, including immunological parameters, were normal. Anti-AchR antibodies were absent. SFEMG from the right EDC muscle showed a slightly increased fibre density of 1-6, blockings 1% and an increased jitter us) (fig b) . EMG from the thenar muscles after repetitive median nerve stimulation revealed a slight increment of 118% after 3/sec-stimulation and an increment of 229% after 50 stimuli with a frequency of 20/sec (fig a) .
These findings were not compatible with a systemic effect of a low dose of botulinum toxin, but suggested an additional presynaptic disturbance of the neuromuscular junction, particularly Lambert-Eaton myasthenic syndrome (LEMS). An In our case the LEMS had been asypmtomatic before the botulinum toxin injections. The additional and reversible effect of botulinum toxin on the neuromus- figure) . A reduction in amplitude of ratio more than 40% at proximal supramaximal stimulation has been accepted as the criterion for conduction block, in the absence of increased duration of compound muscle action potential more than 20%.5 The block was not located at the usual sites of compression, and the segment blocked varied from nerve to nerve. More than one segment with blocks was possible in the same nerve (figure). The neuropathy was asymmetrical. Distal motor latencies were normal. There was proximal slowing in motor conduction velocity in the upper limb nerves (median, ulnar, musculocutaneous), but only moderate slowing in peroneal and tibial posterior nerves (kneeto-ankle segment) (figure). Right median and ulnar nerves F waves were absent. Central motor pathways conduction time was calculated by magnetic stimulation of the brain and this was normal (5-0ms). Radicular conduction (C7-Erb's point) was prolonged.
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